IBSA Institut Biochimique SA   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Lugano Switzerland (1945)
Status: No NME R&D (1945)

Organization Overview

First Clinical Trial
2001
NCT00464607
First Marketed Drug
2006
levothyroxine (Synthroid)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

IBSA Head of R&D Scientific Affairs | IBSA INST BIO | IBSA Institut Biochimique SA | INST BIOCHEM | INSTITUT BIOCHIMIQUE

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Abortion, Threatened (Phase 3)

Athletic Injuries (Phase 4)

Hypothyroidism (Phase 4)

Infertility (Phase 4)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Soft Tissue Injuries (Phase 4)

Thyroiditis (Phase 2)

Thyroiditis, Autoimmune (Phase 2)

Toothache (Phase 3)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 27
  • # of Trial APIs: 13